Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well-Differentiated Pancreatic Neuroendocrine Tumor (NET)

Aaron Vinik,1 Eric Van Cutsem,2 Patricia Niccoli,3 Jean-Luc Raoul,4 Yung-Jue Bang,5 Ivan Borbath,6 Catherine Lombard-Bohas,7 Juan W. Valle,8 Peter Metrakos,9 Denis Smith,10 Jen-Shi Chen,11 Dieter Hörsch,12 Daniel E. Castellano,13 Hagen F. Kennecke,14 Joel Picus,15 Guy Van Hazel,16 Shem Patyna,17 Dongrui Ray Lu,17 Richard C. Chao,17 Eric Raymond,18

1EVMS Strelitz Diabetes Research Center and Neuroendocrine Unit, Norfolk, VA; 2University Hospital Gasthuisberg, Leuven, Belgium; 3University Hospital Timone, Paoli-Calmettes Institute and RENATEN Network, Marseille, France; 4Paoli-Calmettes Institute, Marseille, France; 5Seoul National University Hospital, Seoul, Republic of Korea; 6Cliniques Universitaires Saint-Luc, Brussels, Belgium; 7Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; 8The Christie NHS Foundation Trust, Manchester, United Kingdom; 9McGill University Hospital Centre, Montreal, QC, Canada; 10Medical oncology, University Hospital, Bordeaux, France; 11Chang Gung Memorial Hospital and Chang Gung University, Taipei, Republic of China; 12Zentralklinik Bad Berka GmbH, Bad Berka, Germany; 13Hospital Universitario 12 de Octubre, Madrid, Spain; 14British Columbia Cancer Agency, Vancouver, BC, Canada; 15Washington University School of Medicine, St. Louis, MO; 16University of Western Australia, Perth, Australia; 17Pfizer Oncology, La Jolla, CA; 18Beaujon University Hospital, Clichy, France

Background: In a double-blind phase III trial, sunitinib improved PFS vs. placebo (11.4 vs. 5.5 months; HR: 0.418, 95% CI: 0.263–0.662; P=0.0001) and was well
tolerated in patients with progressive, unresectable, well-differentiated pancreatic NET that had progressed ≤12 months before baseline (Raymond et al, NEJM 2011). Initial OS revealed a benefit for sunitinib over placebo, but median OS was not reached (NR). We now report PFS assessed by BICR and updated median OS.

**Methods:** Patients were randomized 1:1 to sunitinib 37.5 mg on a continuous-daily-dosing schedule or placebo, each with best supportive care. The primary endpoint was PFS; OS was a secondary endpoint. Baseline and on-study CT/MRI scans were evaluated by a 2-reader, 2-time point lock, followed by a sequential locked-read, batch-mode paradigm by blinded, third-party radiologists. Patients in the placebo arm with disease progression were eligible to receive sunitinib in an extension study.

**Results:** 171 patients were randomized (sunitinib, n=86; placebo, n=85) from 6/2007 to 4/2009. The trial ended when an independent data monitoring committee noted efficacy favoring sunitinib and more serious AEs and deaths with placebo. The study was unblinded at closure; patients were offered open-label sunitinib and followed for survival. Median PFS by BICR was 12.6 vs. 5.8 months, sunitinib vs. placebo, respectively (HR: 0.315, 95% CI: 0.181–0.546; P=0.000015). At study end, there were 9 and 21 deaths in the sunitinib and placebo arms (HR: 0.409, 95% CI: 0.187–0.894; P=0.0204). By 6/2010, there were 34 and 39 deaths; median OS was 30.5 (95% CI: 20.6–NR) and 24.4 (95% CI: 16.3–NR) months, respectively (HR: 0.737; 95% CI: 0.465–1.168; P=0.1926). 69% of patients crossed over to sunitinib on progression.

**Conclusion:** BICR of PFS demonstrated a 6.8-month improvement in median PFS with sunitinib, confirming the treatment effect reported with investigator assessment.